iifl-logo

Venus Remedies Ltd Half Yearly Results

302.85
(-2.79%)
Apr 30, 2025|03:57:39 PM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Financials

Particulars (Rupees in Crores.)Sept-2024Mar-2024Sept-2023Mar-2023Sept-2022

Gross Sales

276.06

338.58

262.87

272.54

282.97

Excise Duty

0

0

0

0

0

Net Sales

276.06

338.58

262.87

272.54

282.97

Other Operating Income

0

0

0

0

0

Other Income

12.17

6.27

5.31

7.09

3.23

Total Income

288.23

344.85

268.18

279.63

286.2

Total Expenditure

259.88

307.17

234.68

240

255.49

PBIDT

28.35

37.68

33.5

39.63

30.71

Interest

0.04

-0.03

0.12

-0.14

0.26

PBDT

28.31

37.71

33.38

39.77

30.45

Depreciation

12.39

12.46

13.99

15.51

16.79

Minority Interest Before NP

0

0

0

0

0

Tax

6.26

5.15

7.07

0

0

Deferred Tax

4.92

2.74

1.2

9.92

1.44

Reported Profit After Tax

4.74

17.36

11.12

14.34

12.22

Minority Interest After NP

0

0

0

0

0

Net Profit after Minority Interest

4.74

17.36

11.12

14.34

12.22

Extra-ordinary Items

0

0

0

0

0

Adjusted Profit After Extra-ordinary item

4.74

17.36

11.12

14.34

12.22

EPS (Unit Curr.)

3.54

12.98

8.32

10.73

9.14

Book Value (Unit Curr.)

0

0

0

0

0

Dividend (%)

0

0

0

0

0

Equity

13.37

13.37

13.37

13.37

13.37

Public Shareholding (Number)

0

0

0

0

0

Public Shareholding (%)

0

0

0

0

0

Pledged/Encumbered - No. of Shares

0

0

0

0

0

Pledged/Encumbered - % in Total Promoters Holding

0

0

0

0

0

Pledged/Encumbered - % in Total Equity

0

0

0

0

0

Non Encumbered - No. of Shares

0

0

0

0

0

Non Encumbered - % in Total Promoters Holding

0

0

0

0

0

Non Encumbered - % in Total Equity

0

0

0

0

0

PBIDTM(%)

10.26

11.12

12.74

14.54

10.85

PBDTM(%)

-

-

-

-

-

PATM(%)

1.71

5.12

4.23

5.26

4.31

Venus Remedies: Related NEWS

Venus Remedies Secures Key Approvals, Strengthens Global Market Reach
31 Dec 2024|09:16 PM

The company is now set to further expand into Eastern Europe as this recognition ensures patients and healthcare providers have access to reliable and effective antibiotics.

Read More
Venus Remedies gets approval for pre-filled syringe facility
6 Nov 2024|10:36 AM

Furthermore, the NPRA's recognition will enable Venus Remedies to capitalise on the expanding global demand for enoxaparin.

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.